Tech Seeker (TS)

PsychoGenics Inc (AKA:PGI Drug Discovery LLC)
Profile last edited on: 9/10/2013

CNS drug target validation and compound selection
TS Type
Small Corporation
Year Founded
Last Involved Year

Key People / Management

  Emer Leahy, Ph.D., M.B.A. -- President and CEO

  Vadim Alexandrov, Ph.D., Ph.D. -- V.P., Informatics and IT

  Daniela Brunner, Ph.D -- Sr. V.P., Behavioral Research and Development

  William Fasnacht -- CFO/COO

  Afshin Ghavami, Ph.D. -- V.P., Research Operations

  Taleen Hanania, Ph.D. -- V.P., Behavioral Pharmacology

  Christina Leahy, M.S. -- Sr. Director, Quality Assurance

  David Lowe, Ph.D. -- Head of Science & European Business

  Sylvie Ramboz, Ph.D. -- V.P., Neurodegenerative Disorders

Location Information

215 College Road
Paramus, NJ 07652
   (914) 406-8019

Public Profile

PsychoGenics is a rapidly growing innovative preclinical CNS service provider with expertise in the fields of psychopharmacology, behavioral testing, molecular biology and informatics. The firm has an established service business, with more than 160 repeat pharmaceutical, biotechnology and not-for-profit, domestic and international clients. PsychoGenics offers over 80 different behavioral tests to phenotype rodent disease models and test drug candidates in the areas of psychiatric and neurodegenerative disorders, pain and inflammation, and spinal cord and traumatic brain injury. The company is able to compliment their behavioral expertise with other capabilities, including electrophysiology, molecular biology, neurogenesis, state of the art microdialysis and a variety of in-licensed transgenic mouse models that support research in areas such as Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, Autism spectrum disorders, psychosis/schizophrenia, Spinal Muscular Atrophy (SMA), muscular dystrophy and other muscle disorders.

Extent of SBIR involvement

User Avatar

Synopsis: Techseeker Business Condition

Privately Held
Stock Info
Received SBIR $$

SBIR firms in the news

There are no news available.